CAPVAXIVE Solution for Injection
Product details
Registration number: SIN17471P
Classification: Prescription Only
Active ingredients:
- (MBC) Pneumococcal Polysaccharide Serotype 10A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 11A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 12F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 15A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 16F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 17F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 20A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 23A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 23B conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 24F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 31 conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 35B conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 8 conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 9N conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide de-O-acetylated Serotype 15B conjugated to CRM197
Strength:
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
Dosage form: INJECTION, SOLUTION
Route: INTRAMUSCULAR
Registrant: MSD PHARMA (SINGAPORE) PTE. LTD.
ATC code: J07AL02
HSA approval date: 20 February 2026
Manufacturer(s): MSD International GmbH
Manufacturing country/countries: IRELAND
What are the HSA registration number and classification for CAPVAXIVE Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN17471P
Classification: Prescription Only
What active ingredients and strength are recorded for CAPVAXIVE Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Active ingredients:
- (MBC) Pneumococcal Polysaccharide Serotype 10A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 11A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 12F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 15A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 16F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 17F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 19A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 20A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 22F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 23A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 23B conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 24F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 3 conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 31 conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 33F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 35B conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 6A conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 7F conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 8 conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide Serotype 9N conjugated to CRM197
- (MBC) Pneumococcal Polysaccharide de-O-acetylated Serotype 15B conjugated to CRM197
Strength:
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
- 4ug/0.5mL
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for CAPVAXIVE Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, SOLUTION
Route: INTRAMUSCULAR
Who is the recorded registrant for CAPVAXIVE Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Registrant: MSD PHARMA (SINGAPORE) PTE. LTD.
Which manufacturers and countries are listed for CAPVAXIVE Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s): MSD International GmbH
Manufacturing country/countries: IRELAND
Where can I look up CAPVAXIVE Solution for Injection in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN17471P or the exact product name CAPVAXIVE Solution for Injection. The general register link does not preselect this product.
What are the source dates for this CAPVAXIVE Solution for Injection record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this CAPVAXIVE Solution for Injection record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN17471P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)